{"id":46765,"date":"2022-07-31T19:02:11","date_gmt":"2022-07-31T17:02:11","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/c2ns-new-blood-test-combining-p-tau217-ratio-with-a%ce%b242-40-ratio-points-to-accuracy-levels-comparable-to-existing-standards-of-care-for-amyloid-diagnosis-in-the-evaluation-of-patients-wit\/"},"modified":"2022-07-31T19:02:11","modified_gmt":"2022-07-31T17:02:11","slug":"c2ns-new-blood-test-combining-p-tau217-ratio-with-a%ce%b242-40-ratio-points-to-accuracy-levels-comparable-to-existing-standards-of-care-for-amyloid-diagnosis-in-the-evaluation-of-patients-wit","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/c2ns-new-blood-test-combining-p-tau217-ratio-with-a%ce%b242-40-ratio-points-to-accuracy-levels-comparable-to-existing-standards-of-care-for-amyloid-diagnosis-in-the-evaluation-of-patients-wit\/","title":{"rendered":"C2N\u2019s New Blood Test Combining p-tau217 Ratio with A\u03b242\/40 Ratio Points to Accuracy Levels Comparable to Existing Standards of Care for Amyloid Diagnosis in the Evaluation of Patients with Cognitive Impairment"},"content":{"rendered":"
\n

SAN DIEGO–(BUSINESS WIRE)–#AAIC2022<\/a>–Data released from C2<\/sub>N Diagnostics<\/a>, presented today at the Alzheimer’s Association International Conference, demonstrated that a blood test combining the A\u03b242\/40 ratio, a component of C2<\/sub>N\u2019s commercially available PrecivityADTM<\/sup> blood test, with a unique p-tau217 ratio leads to testing performance that points to accuracy comparable to more complex amyloid PET imaging and invasive cerebrospinal fluid tests in identifying Alzheimer\u2019s brain pathology.\n<\/p>\n

<\/a><\/p>\n

\nThe study, based on a difficult-to-diagnose population of 221 individuals dealing with cognitive impairment of unclear etiology who were originally part of the IDEAS study<\/a>, observed that adding C2<\/sub>N\u2019s proprietary p-tau217 ratio measurement to its existing A\u03b242\/40 ratio measurement greatly facilitates the identification of patients with Alzheimer\u2019s brain pathology, even at the earliest stages of disease accumulation. The integrated score derived from the p-tau217 ratio and A\u03b242\/40 ratio achieved an AUC performance of 0.96 and accuracy of 90% when compared with quantitative amyloid PET results.\n<\/p>\n

\nC2<\/sub>N introduced the clinically validated PrecivityAD\u2122 blood test<\/a> over a year ago to help healthcare providers determine the presence or absence of amyloid plaques in the brain, a hallmark sign of Alzheimer\u2019s disease.\n<\/p>\n

\nDr. Joel Braunstein, C\u2082N\u2019s CEO, says, \u201cThis news is an exciting and impactful milestone for our company and the Alzheimer\u2019s field, in general. It reflects a tireless effort from our extraordinary team at C2<\/sub>N to continue innovating for the ultimate benefit of patient welfare. We are committed to transforming the way in which patients around the world receive a timely and accurate diagnosis for their memory concerns. Proper diagnosis is the first step in a patient\u2019s journey to receive the care they need for their brain health. The progress we are making with the development of a logistically simple, cost-effective, and widely accessible blood test that determines the presence or absence of Alzheimer\u2019s brain pathology with similar levels of performance to more invasive testing standards brings us one step closer to realizing our ambitions.\u201d\n<\/p>\n

\nBlood Test Benefits to Patients<\/b>\n<\/p>\n

\nIn comparison to a plasma test, amyloid PET imaging is costly, a difficult procedure to access, and exposes individuals who do not have Alzheimer\u2019s disease to unnecessary radiation. Cerebrospinal fluid biomarkers require a spinal tap, which is a needle insertion into the lower part of the back.\n<\/p>\n

\nThe new C2<\/sub>N assay relies on high-resolution mass spectrometry to precisely measure from a single sample of blood multiple different proteins implicated in Alzheimer\u2019s-related brain changes. These markers include the beta-amyloid 42 and 40 peptides, and different phosphorylated and nonphosphorylated forms of the tau protein, including forms with phosphorylation at the tau217 and tau181 sites. Combining the A\u03b242\/40 ratio with the p-tau217\/non-ptau217 ratio into a single integrated score resulted in superior performance to identify the presence or absence of brain amyloid plaques.\n<\/p>\n

\nIn May, C\u2082N Diagnostics introduced<\/a> its p-tau Multi-Analyte Assay for Research Use Only. The clinical results presented today reflect an evolution of progress with both that assay and C2<\/sub>N\u2019s original PrecivityAD\u2122 test. Dr. Braunstein says, \u201cWe look forward to sharing even further developments in the weeks and months ahead as we expand our menu of advanced clinical diagnostic services for the betterment of patient care.\u201d\n<\/p>\n

\nAbout C2<\/sub>N Diagnostics, LLC
\n
<\/b>C2<\/sub>N<\/i> Diagnostics is a specialty diagnostics company with a vision to bring Clarity Through Innovation\u2122. C2<\/sub>N strives to provide exceptional laboratory services and products in the field of brain health. C2<\/sub>N\u2019s biomarker services and products are used for: clinical decision making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. For more information visit <\/i>www.C2N.com<\/i><\/a>.<\/i>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMEDIA:
\n
Adam Shapiro
\n
Adam.Shapiro@ASPR.bz<\/a>
202-427-3603\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO–(BUSINESS WIRE)–#AAIC2022–Data released from C2N Diagnostics, presented today at the Alzheimer’s Association International Conference, demonstrated that a blood test combining the A\u03b242\/40 ratio, a component of C2N\u2019s commercially available PrecivityADTM blood test, with a unique p-tau217 ratio leads to testing performance that points to accuracy comparable to more complex amyloid PET imaging and invasive … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46765","6":"format-standard","7":"category-industry"},"yoast_head":"\nC2N\u2019s New Blood Test Combining p-tau217 Ratio with A\u03b242\/40 Ratio Points to Accuracy Levels Comparable to Existing Standards of Care for Amyloid Diagnosis in the Evaluation of Patients with Cognitive Impairment - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/c2ns-new-blood-test-combining-p-tau217-ratio-with-a\u03b242-40-ratio-points-to-accuracy-levels-comparable-to-existing-standards-of-care-for-amyloid-diagnosis-in-the-evaluation-of-patients-wit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"C2N\u2019s New Blood Test Combining p-tau217 Ratio with A\u03b242\/40 Ratio Points to Accuracy Levels Comparable to Existing Standards of Care for Amyloid Diagnosis in the Evaluation of Patients with Cognitive Impairment - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO–(BUSINESS WIRE)–#AAIC2022–Data released from C2N Diagnostics, presented today at the Alzheimer’s Association International Conference, demonstrated that a blood test combining the A\u03b242\/40 ratio, a component of C2N\u2019s commercially available PrecivityADTM blood test, with a unique p-tau217 ratio leads to testing performance that points to accuracy comparable to more complex amyloid PET imaging and invasive ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/c2ns-new-blood-test-combining-p-tau217-ratio-with-a\u03b242-40-ratio-points-to-accuracy-levels-comparable-to-existing-standards-of-care-for-amyloid-diagnosis-in-the-evaluation-of-patients-wit\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-31T17:02:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220731005031\/en\/1530034\/21\/Logos.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/c2ns-new-blood-test-combining-p-tau217-ratio-with-a%ce%b242-40-ratio-points-to-accuracy-levels-comparable-to-existing-standards-of-care-for-amyloid-diagnosis-in-the-evaluation-of-patients-wit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/c2ns-new-blood-test-combining-p-tau217-ratio-with-a%ce%b242-40-ratio-points-to-accuracy-levels-comparable-to-existing-standards-of-care-for-amyloid-diagnosis-in-the-evaluation-of-patients-wit\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"C2N\u2019s New Blood Test Combining p-tau217 Ratio with A\u03b242\\\/40 Ratio Points to Accuracy Levels Comparable to Existing Standards of Care for Amyloid Diagnosis in the Evaluation of Patients with Cognitive Impairment\",\"datePublished\":\"2022-07-31T17:02:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/c2ns-new-blood-test-combining-p-tau217-ratio-with-a%ce%b242-40-ratio-points-to-accuracy-levels-comparable-to-existing-standards-of-care-for-amyloid-diagnosis-in-the-evaluation-of-patients-wit\\\/\"},\"wordCount\":688,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/c2ns-new-blood-test-combining-p-tau217-ratio-with-a%ce%b242-40-ratio-points-to-accuracy-levels-comparable-to-existing-standards-of-care-for-amyloid-diagnosis-in-the-evaluation-of-patients-wit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220731005031\\\/en\\\/1530034\\\/21\\\/Logos.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/c2ns-new-blood-test-combining-p-tau217-ratio-with-a%ce%b242-40-ratio-points-to-accuracy-levels-comparable-to-existing-standards-of-care-for-amyloid-diagnosis-in-the-evaluation-of-patients-wit\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/c2ns-new-blood-test-combining-p-tau217-ratio-with-a%ce%b242-40-ratio-points-to-accuracy-levels-comparable-to-existing-standards-of-care-for-amyloid-diagnosis-in-the-evaluation-of-patients-wit\\\/\",\"name\":\"C2N\u2019s New Blood Test Combining p-tau217 Ratio with A\u03b242\\\/40 Ratio Points to Accuracy Levels Comparable to Existing Standards of Care for Amyloid Diagnosis in the Evaluation of Patients with Cognitive Impairment - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/c2ns-new-blood-test-combining-p-tau217-ratio-with-a%ce%b242-40-ratio-points-to-accuracy-levels-comparable-to-existing-standards-of-care-for-amyloid-diagnosis-in-the-evaluation-of-patients-wit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/c2ns-new-blood-test-combining-p-tau217-ratio-with-a%ce%b242-40-ratio-points-to-accuracy-levels-comparable-to-existing-standards-of-care-for-amyloid-diagnosis-in-the-evaluation-of-patients-wit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220731005031\\\/en\\\/1530034\\\/21\\\/Logos.jpg\",\"datePublished\":\"2022-07-31T17:02:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/c2ns-new-blood-test-combining-p-tau217-ratio-with-a%ce%b242-40-ratio-points-to-accuracy-levels-comparable-to-existing-standards-of-care-for-amyloid-diagnosis-in-the-evaluation-of-patients-wit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/c2ns-new-blood-test-combining-p-tau217-ratio-with-a%ce%b242-40-ratio-points-to-accuracy-levels-comparable-to-existing-standards-of-care-for-amyloid-diagnosis-in-the-evaluation-of-patients-wit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/c2ns-new-blood-test-combining-p-tau217-ratio-with-a%ce%b242-40-ratio-points-to-accuracy-levels-comparable-to-existing-standards-of-care-for-amyloid-diagnosis-in-the-evaluation-of-patients-wit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220731005031\\\/en\\\/1530034\\\/21\\\/Logos.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220731005031\\\/en\\\/1530034\\\/21\\\/Logos.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/c2ns-new-blood-test-combining-p-tau217-ratio-with-a%ce%b242-40-ratio-points-to-accuracy-levels-comparable-to-existing-standards-of-care-for-amyloid-diagnosis-in-the-evaluation-of-patients-wit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"C2N\u2019s New Blood Test Combining p-tau217 Ratio with A\u03b242\\\/40 Ratio Points to Accuracy Levels Comparable to Existing Standards of Care for Amyloid Diagnosis in the Evaluation of Patients with Cognitive Impairment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"C2N\u2019s New Blood Test Combining p-tau217 Ratio with A\u03b242\/40 Ratio Points to Accuracy Levels Comparable to Existing Standards of Care for Amyloid Diagnosis in the Evaluation of Patients with Cognitive Impairment - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/c2ns-new-blood-test-combining-p-tau217-ratio-with-a\u03b242-40-ratio-points-to-accuracy-levels-comparable-to-existing-standards-of-care-for-amyloid-diagnosis-in-the-evaluation-of-patients-wit\/","og_locale":"en_US","og_type":"article","og_title":"C2N\u2019s New Blood Test Combining p-tau217 Ratio with A\u03b242\/40 Ratio Points to Accuracy Levels Comparable to Existing Standards of Care for Amyloid Diagnosis in the Evaluation of Patients with Cognitive Impairment - Pharma Trend","og_description":"SAN DIEGO–(BUSINESS WIRE)–#AAIC2022–Data released from C2N Diagnostics, presented today at the Alzheimer’s Association International Conference, demonstrated that a blood test combining the A\u03b242\/40 ratio, a component of C2N\u2019s commercially available PrecivityADTM blood test, with a unique p-tau217 ratio leads to testing performance that points to accuracy comparable to more complex amyloid PET imaging and invasive ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/c2ns-new-blood-test-combining-p-tau217-ratio-with-a\u03b242-40-ratio-points-to-accuracy-levels-comparable-to-existing-standards-of-care-for-amyloid-diagnosis-in-the-evaluation-of-patients-wit\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-31T17:02:11+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220731005031\/en\/1530034\/21\/Logos.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/c2ns-new-blood-test-combining-p-tau217-ratio-with-a%ce%b242-40-ratio-points-to-accuracy-levels-comparable-to-existing-standards-of-care-for-amyloid-diagnosis-in-the-evaluation-of-patients-wit\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/c2ns-new-blood-test-combining-p-tau217-ratio-with-a%ce%b242-40-ratio-points-to-accuracy-levels-comparable-to-existing-standards-of-care-for-amyloid-diagnosis-in-the-evaluation-of-patients-wit\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"C2N\u2019s New Blood Test Combining p-tau217 Ratio with A\u03b242\/40 Ratio Points to Accuracy Levels Comparable to Existing Standards of Care for Amyloid Diagnosis in the Evaluation of Patients with Cognitive Impairment","datePublished":"2022-07-31T17:02:11+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/c2ns-new-blood-test-combining-p-tau217-ratio-with-a%ce%b242-40-ratio-points-to-accuracy-levels-comparable-to-existing-standards-of-care-for-amyloid-diagnosis-in-the-evaluation-of-patients-wit\/"},"wordCount":688,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/c2ns-new-blood-test-combining-p-tau217-ratio-with-a%ce%b242-40-ratio-points-to-accuracy-levels-comparable-to-existing-standards-of-care-for-amyloid-diagnosis-in-the-evaluation-of-patients-wit\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220731005031\/en\/1530034\/21\/Logos.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/c2ns-new-blood-test-combining-p-tau217-ratio-with-a%ce%b242-40-ratio-points-to-accuracy-levels-comparable-to-existing-standards-of-care-for-amyloid-diagnosis-in-the-evaluation-of-patients-wit\/","url":"https:\/\/pharma-trend.com\/en\/c2ns-new-blood-test-combining-p-tau217-ratio-with-a%ce%b242-40-ratio-points-to-accuracy-levels-comparable-to-existing-standards-of-care-for-amyloid-diagnosis-in-the-evaluation-of-patients-wit\/","name":"C2N\u2019s New Blood Test Combining p-tau217 Ratio with A\u03b242\/40 Ratio Points to Accuracy Levels Comparable to Existing Standards of Care for Amyloid Diagnosis in the Evaluation of Patients with Cognitive Impairment - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/c2ns-new-blood-test-combining-p-tau217-ratio-with-a%ce%b242-40-ratio-points-to-accuracy-levels-comparable-to-existing-standards-of-care-for-amyloid-diagnosis-in-the-evaluation-of-patients-wit\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/c2ns-new-blood-test-combining-p-tau217-ratio-with-a%ce%b242-40-ratio-points-to-accuracy-levels-comparable-to-existing-standards-of-care-for-amyloid-diagnosis-in-the-evaluation-of-patients-wit\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220731005031\/en\/1530034\/21\/Logos.jpg","datePublished":"2022-07-31T17:02:11+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/c2ns-new-blood-test-combining-p-tau217-ratio-with-a%ce%b242-40-ratio-points-to-accuracy-levels-comparable-to-existing-standards-of-care-for-amyloid-diagnosis-in-the-evaluation-of-patients-wit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/c2ns-new-blood-test-combining-p-tau217-ratio-with-a%ce%b242-40-ratio-points-to-accuracy-levels-comparable-to-existing-standards-of-care-for-amyloid-diagnosis-in-the-evaluation-of-patients-wit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/c2ns-new-blood-test-combining-p-tau217-ratio-with-a%ce%b242-40-ratio-points-to-accuracy-levels-comparable-to-existing-standards-of-care-for-amyloid-diagnosis-in-the-evaluation-of-patients-wit\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220731005031\/en\/1530034\/21\/Logos.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220731005031\/en\/1530034\/21\/Logos.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/c2ns-new-blood-test-combining-p-tau217-ratio-with-a%ce%b242-40-ratio-points-to-accuracy-levels-comparable-to-existing-standards-of-care-for-amyloid-diagnosis-in-the-evaluation-of-patients-wit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"C2N\u2019s New Blood Test Combining p-tau217 Ratio with A\u03b242\/40 Ratio Points to Accuracy Levels Comparable to Existing Standards of Care for Amyloid Diagnosis in the Evaluation of Patients with Cognitive Impairment"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46765","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46765"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46765\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46765"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46765"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46765"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}